September 28, 2026

California firm licenses ‘potent’ anti-measles antibodies from Vanderbilt Health for development, clinical testing

The human monoclonal antibodies were isolated from two individuals who had been infected by measles. Further development and clinical testing could lead to the first monoclonal antibody therapy against the highly infectious respiratory virus.

By Bill Snyder

April 3, 2026

Vanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment

“These antibodies hold significant promise to be used in people who are at risk of measles, but who cannot respond to the measles vaccine due to their weakened immune systems,” said James Crowe Jr., MD, whose research team isolated the human monoclonal antibodies.

By Bill Snyder

July 8, 2025

Vanderbilt, Parse Biosciences scientists envision an antibody ‘atlas’ for measles, mumps, rubella

Researchers will scan the landscape of plasmablasts, the first antibody-producing, B-type immune cells that respond to MMR infection.

By Bill Snyder